Dr. Raghavan, drawing on his leadership role at the nexus of clinical care and discovery science, will highlight the issues behind the topics that will be covered during the Summit.

Mr. Brennan is both CEO of AstraZeneca and current Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA). Under Brennan’s leadership, AstraZeneca has significantly advanced as a global leader in the war against cancer and he has expanded AstraZeneca’s capabilities into new areas of technology. Arimidex is a market leader for breast cancer therapy and AstraZeneca’s acquisition of MedImmune positions the company to assert its biologics expertise.

Dr. Vasella has been CEO of Novartis since the merger that created the company in 1996. He is leading an organization with a vibrant research and development program and has overseen the building of one of the largest oncology pipelines in the industry. Novartis’ introduction of Gleevec in 2001 marked the entry of the first tyrosine kinase inhibitor and set the standard for the prototypical targeted cancer therapy. Gleevec is one of the Top 10 biologic drugs with annual revenues of $3.7 billion.

Leaders from multiple fronts in the war on cancer will reflect on the great challenges in treatment and molecular prognostication of cancer and the prospects for meaningful progress in those areas in the next decade.

• William Hait, MD, PhD
  Senior Vice President, Worldwide Head, Hematology and Oncology, Johnson & Johnson
• Tom Miller
  Chief Executive Officer, Workflow Solutions, Siemens
• Sir Bruce Ponder, MD, PhD
  Director, Cancer Research UK Cambridge Research Institute
• Kári Stefánsson, MD
  Chief Executive Officer, deCODE genetics

A partial nephrectomy will be demonstrated using the daVinci robotic surgical assistant. This procedure will detail the challenges inherent in a partial nephrectomy and the benefit of using robotic assistance.

Few recent breakthroughs in health care have received the attention that genomic testing has. Top leaders from throughout this emerging industry will discuss the prospects for it as a meaningful tool for clinicians and patients in the coming years.

• Greg Lucier
  Chief Executive Officer, Life Technologies
• Edward McCabe, MD, PhD
  President, American Society of Human Genetics
• Wayne Rosenkrans, Jr., PhD
  Chief Executive Officer, Personalized Medicine Coalition
• Dietrich Stephan, PhD
  Co-Founder & Chief Scientific Officer, Navigenics
• Anne Wojcicki
  Co-Founder, 23 and Me

The CEO of the world’s largest IT company will provide his unique perspective on the state of health care IT. He will discuss its impact on all aspects of the health care industry and the prospects for achieving its long sought promise for better outcomes, greater efficiency and previously unachievable medical innovations. IBM is the largest U.S. holder of intellectual property in the world, with well over 3,000 patents and its former top IP Counsel is the new head of the US PTO.

A quiet revolution has been taking place in the use of radiation technology to treat cancer. Chief executives from throughout the industry will discuss why, what’s new, and where the technology is headed.

• Jean Marc Andral
  President, Advanced Radio Therapy, IBA
• Shawn Guse
  Vice President International Operations, TomoTherapy
• Tomas Puusepp
  Chief Executive Officer, Elekta
• Euan Thomson, PhD
  Chief Executive Officer, Accuray
• Dow Wilson
  President, Oncology Systems, Varian

Fred Hassan
Chief Executive Officer, Schering-Plough

One of the top business correspondents and a major pharmaceutical CEO widely recognized for the high quality of his innovation pipeline will have an insider’s discussion on how the industry is changing, the challenges to innovation—including the decline in new drug approvals—and the prospects for future innovation in an era of reform and consolidation. Mr. Hassan’s position as an architect of the modern pharmaceutical industry was highlighted by the recent merger of Schering-Plough with Merck.

Many large health care players have established captive venture funds. This panel of corporate and venture leaders, moderated by Maria Bartiromo, will examine the success of the model, its current challenges, and how it affects the development of new technology.

• Darren Carroll
  Vice President, New Ventures Division, Eli Lilly
• Roy Davis
  President, Johnson & Johnson Development Corporation
• Ven Manda
  Vice President, Medtronic Ventures and New Therapies
• Harry Rein
  General Partner, Foundation Medical Partners
• Mark Vachon
  President and Chief Executive Officer, Americas, GE Healthcare

As the innovation mandate grows throughout the medical products industry, some companies have responded by enhancing internal capabilities while others have found innovation through collaboration and acquisition. This select panel of CEOs representing leading biotechnology, pharmaceutical, life science tools, and diagnostic companies, debates the current merits of the different approaches.

• Sol Barer, PhD
  Chief Executive Officer, Celgene
• Fred Hassan
  Chief Executive Officer, Schering-Plough
• Greg Lucier
  Chief Executive Officer, Life Technologies
• Randy Scott, PhD
  Founder and Executive Chairman, Genomic Health

Improving the quality of dietary intake is at the front lines of public health, cost control and disease management. One of America’s top chefs and the Clinic’s own wellness czar demonstrate how “healthful” and “delicious” can describe the same dish.

• William Barum
  Senior Director, Operational Support Services, Cleveland Clinic
• Steve Schimoler
  Chef and Partner, Crop Bistro & Bar

One of America’s top sommeliers will be on hand for this audience participation session on selecting wines to complement healthful foods.

David Brooks has become one of the nation’s most influential newspaper columnists. His insightful New York Times column provides penetrating analysis and is a must-read for decision makers throughout government and the private sector. He has recently emerged as an important voice in the health care debate. He is also a featured commentator on “The News Hour with Jim Lehrer.”

An aggressive brain tumor will be treated using a novel hyperthermia device within an interventional magnetic resonance imaging scanner.

This panel consisting of hands-on leaders from the industry and NIH who will examine progress over the past five years on new targeted, biologic and chemotherapeutic agents and how they have changed patient outcomes.

• James Doroshow, MD
  Division Director, National Cancer Institute
• David Epstein
  President & Chief Executive Officer, Novartis Oncology, Novartis Molecular Diagnostics
• Richard Gaynor, MD
  Vice President, Cancer Research and Global Oncology, Lilly
• Richard Scheller, PhD
  Executive Vice President, Genentech Research and Early Development

The challenges, cost, and conduct of clinical trials and a preview of innovations to come in use of drugs and biologics for personalized oncology and cancer prevention is the focus of this panel of clinical, corporate, and research oncology leaders.

• Richard Schilsky, MD
  Immediate Past President, American Society of Clinical Oncology
• Nancy Simonian, MD
  Chief Medical Officer, Millennium: The Takeda Oncology Company
• Mark Trusheim
  President, Co-Bio Consulting
• John Wigginton, MD
  Director, Discovery Oncology, Bristol Myers Squibb

Leaders and investors at the center of the national health care debate will examine, in detail, how issues that affect innovation at the operating level will change, including reimbursement and product approval.

• Edward Buckley
  Director of Economic Policy, Biotechnology Industry Organization
• David Nexon
  Senior Executive Vice President, AdvaMed
• Beth Seidenberg, MD
  Partner, Kleiner Perkins Caufield & Byers
• Richard Smith
  Senior Vice President, PhRMA

Cleveland Clinic’s widely anticipated annual Top 10 medical breakthroughs will be unveiled by a panel of the Clinic’s top practitioners.

Richard Clark will share his first-hand perspectives as one of the leaders who is reshaping the industry and its approach to medical innovation. Under his stewardship, he has led the acquisition of Schering-Plough and engineered a promising new anti-cancer partnership with AstraZeneca. Clark has had a 36-year career with Merck, beginning as a quality control inspector and being chosen CEO in 2005.

Few organizations affect health care innovation worldwide more than the US FDA. As President Obama’s choice to lead the FDA, Dr. Hamburg will share her vision and priorities as she guides the agency in a period of fundamental reform and economic challenges.